Drugs / Thymosin β4
Thymosin β4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05485818 | Nov 2020 → Sep 2021 | acute myocardial infarction | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-05 | RegeneRx Biopharmaceuticals, Inc. | Results New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease regenerx.com ↗
According to the researchers, among other findings, Tβ4 over-expression in the mouse models alone showed less amyloid beta peptide, or amyloid deposits, which correlates with the clinical status of the patient. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-10-05 | RegeneRx Biopharmaceuticals, Inc. | New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease regenerx.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymosin β4 | “12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）” NCT05485818 ↗ |
| Known as | Recombinant Human Thymosin β4 | “12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）” NCT05485818 ↗ |
| Known as | thymosin beta 4 | “this review will focus on the role of a promising candidate, thymosin beta 4 (Tβ4) in cardioprotection” PMID 22236126 ↗ 2012 |
| Known as | Tβ4 | “this review will focus on the role of a promising candidate, thymosin beta 4 (Tβ4) in cardioprotection” PMID 22236126 ↗ 2012 |
| Modality | Protein / enzyme biologic | “Thymosin β4 protein therapy for cardiac repair.” PMID 22236126 ↗ 2012 |
| Route | Intravenous | “（intravenous injection）” NCT05485818 ↗ |